Relapsing Malaria: A Case Report of Primaquine Resistance

Abstract

Primaquine (an 8-aminoquinoline malarial therapy) is the only FDA-approved therapy to treat the hypnozoite stage of P. vivax. We think of relapse occurring because of parasitic resistance or poor compliance secondary to drug toxicities. However, in patients with repeated treatment failure, we must consider CYP-450 mutations affecting drug metabolism as an… (More)
DOI: 10.1155/2018/9720823

Topics

  • Presentations referencing similar topics